China's State Drug Administration will give priority to reviewing Pamiparib's application for new drugs.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
the National Drug Administration of China (NMPA) Drug Evaluation Center (CDE) has granted Pamiparib new drug review priority, the !---- company announced today.Pamiparib is a research inhibitor targeting PARP1 and PARP2 for the treatment of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have received two or more chemotherapy treatments. "We look forward to presenting the clinical data of Pamiparib at the upcoming medical conference," said Dr. Yong Ben, Chief Medical Officer of Immuno-Oncology at the.the key Phase II part of the Phase I/II clinical trial (NCT03333915), which recruited at least 113 Chinese patients with advanced epithelial ovarian cancer (including fallopian tube or primary peritoneal cancer) or advanced endometrial-like epithelial cancer who underwent more than two standard chemotherapy sessions.although, literally, BRCA' full name, BREast CAncer- gene, is a breast cancer susceptibility gene, the BRCA gene mutation is also associated with hereditary ovarian cancer..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
